Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice.

The transforming rat Her-2/neu oncogene embedded into the genome of virgin transgenic BALB/c mice (BALB-neuT) provokes the development of an invasive carcinoma in each of their 10 mammary glands. i.m. vaccination with DNA plasmids coding for the extracellular and transmembrane domains of the protein product of the Her-2/neu oncogene started when mice already display multifocal in situ carcinomas temporarily halts neoplastic progression, but all mice develop a tumor by week 43. By contrast, progressive clearance of neoplastic lesions and complete protection of all 1-year-old mice are achieved when the same plasmids are electroporated at 10-week intervals. Pathological findings, in vitro tests, and the results from the immunization of both IFN-gamma and immunoglobulin gene knockout BALB-neuT mice, and of adoptive transfer experiments, all suggest that tumor clearance rests on the combination of antibodies and IFN-gamma-releasing T cells. These findings show that an appropriate vaccine effectively inhibits the progression of multifocal preneoplastic lesions.

[1]  G. Forni,et al.  Helper strategy in tumor immunology: Expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy , 1988, Cancer and Metastasis Reviews.

[2]  Yosef Yarden,et al.  A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors , 1997, Oncogene.

[3]  P. Musiani,et al.  Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[4]  Piero Musiani,et al.  DNA Vaccination Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice1 2 , 2000, The Journal of Immunology.

[5]  G. Forni,et al.  Prophylactic cancer vaccines. , 2002, Current opinion in immunology.

[6]  R. Xu,et al.  Amplification of Her-2/neu Gene in Her-2/neu-Overexpressing and -Nonexpressing Breast Carcinomas and Their Synchronous Benign, Premalignant, and Metastatic Lesions Detected by FISH in Archival Material , 2002, Modern Pathology.

[7]  I. M. Belyakov,et al.  Strategies for designing and optimizing new generation vaccines , 2001, Nature Reviews Immunology.

[8]  T. Boon.  Antigenic tumor cell variants obtained with mutagens. , 1983, Advances in cancer research.

[9]  J. Ulmer,et al.  Increased DNA Vaccine Delivery and Immunogenicity by Electroporation In Vivo , 2000, The Journal of Immunology.

[10]  P. Musiani,et al.  LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. , 2003, Cancer research.

[11]  P. Musiani,et al.  Cytokines, tumour-cell death and immunogenicity: a question of choice. , 1997, Immunology today.

[12]  M. Bureau,et al.  High-efficiency gene transfer into skeletal muscle mediated by electric pulses. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[13]  P. Musiani,et al.  Salivary carcinoma in HER‐2/neu transgenic male mice: An angiogenic switch is not required for tumor onset and progression , 2000, International journal of cancer.

[14]  P. Musiani,et al.  Interleukin 12-activated lymphocytes influence tumor genetic programs. , 2001, Cancer research.

[15]  G. Trinchieri,et al.  Biology of Natural Killer Cells , 1989, Advances in Immunology.

[16]  P. Musiani,et al.  Immunoprevention of cancer: is the time ripe? , 2000, Cancer research.

[17]  T. Kipps,et al.  DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors. , 1998, Cancer research.

[18]  G Hewinson,et al.  DNA Injection in Combination with Electroporation: a Novel Method for Vaccination of Farmed Ruminants , 2003, Scandinavian journal of immunology.

[19]  G. Klein,et al.  Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. , 1960, Cancer research.

[20]  Piero Musiani,et al.  Interleukin 12–mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice , 1998, The Journal of experimental medicine.

[21]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[22]  Piero Musiani,et al.  Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. , 2003, The Journal of clinical investigation.

[23]  P. Leder,et al.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.

[24]  Piero Musiani,et al.  Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice , 2001, The Journal of experimental medicine.

[25]  Jonathan J. Lewis,et al.  Coupling and Uncoupling of Tumor Immunity and Autoimmunity , 1999, The Journal of experimental medicine.

[26]  H. Aihara,et al.  Gene transfer into muscle by electroporation in vivo. , 1998, Nature biotechnology.

[27]  P. Lollini,et al.  Cancer immunoprevention: tracking down persistent tumor antigens. , 2003, Trends in immunology.

[28]  T. Blankenstein,et al.  B cells inhibit induction of T cell-dependent tumor immunity , 1998, Nature Medicine.

[29]  P. Musiani,et al.  Insertion of the DNA for the 163–171 peptide of IL1β enables a DNA vaccine encoding p185neu to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice , 2001, Gene Therapy.

[30]  H. Ikeda,et al.  Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. , 1997, Journal of immunology.

[31]  E. Jaffee,et al.  The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. , 2001, Cancer research.

[32]  Makoto Katsumata,et al.  Prevention of breast tumour development in vivo by downregulation of the p185neureceptor , 1995, Nature Medicine.

[33]  T. Schumacher,et al.  Can the Low-Avidity Self-Specific T Cell Repertoire Be Exploited for Tumor Rejection?1 , 2002, The Journal of Immunology.

[34]  G. Forni,et al.  Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. , 1992, Journal of immunology.